These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 31991336)

  • 21. Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer.
    Feng J; Fang H; Wang X; Jia Y; Zhang L; Jiao J; Zhang J; Gu L; Xu W
    Cancer Biol Ther; 2011 Mar; 11(5):477-89. PubMed ID: 21263218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
    Liang X; Zang J; Li X; Tang S; Huang M; Geng M; Chou CJ; Li C; Cao Y; Xu W; Liu H; Zhang Y
    J Med Chem; 2019 Apr; 62(8):3898-3923. PubMed ID: 30901208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
    Jiao J; Fang H; Wang X; Guan P; Yuan Y; Xu W
    Eur J Med Chem; 2009 Nov; 44(11):4470-6. PubMed ID: 19608304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model.
    Routholla G; Pulya S; Patel T; Adhikari N; Abdul Amin S; Paul M; Bhagavatula S; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Dec; 117():105446. PubMed ID: 34717237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors.
    Li Y; Wang Y; Xie N; Xu M; Qian P; Zhao Y; Li S
    Eur J Med Chem; 2015 Jul; 100():270-6. PubMed ID: 26140961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
    Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
    Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
    Lee HY; Tsai AC; Chen MC; Shen PJ; Cheng YC; Kuo CC; Pan SL; Liu YM; Liu JF; Yeh TK; Wang JC; Chang CY; Chang JY; Liou JP
    J Med Chem; 2014 May; 57(10):4009-22. PubMed ID: 24766560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
    Pan T; Dan Y; Guo D; Jiang J; Ran D; Zhang L; Tian B; Yuan J; Yu Y; Gan Z
    Eur J Med Chem; 2021 Nov; 224():113672. PubMed ID: 34237620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indirubin Derivatives as Dual Inhibitors Targeting Cyclin-Dependent Kinase and Histone Deacetylase for Treating Cancer.
    Cao Z; Yang F; Wang J; Gu Z; Lin S; Wang P; An J; Liu T; Li Y; Li Y; Lin H; Zhao Y; He B
    J Med Chem; 2021 Oct; 64(20):15280-15296. PubMed ID: 34624191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
    Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
    PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
    Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
    J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps.
    Fan W; Zhang L; Wang X; Jia H; Zhang L
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):707-718. PubMed ID: 33663315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis.
    Huang YC; Huang FI; Mehndiratta S; Lai SC; Liou JP; Yang CR
    Oncotarget; 2015 Jul; 6(21):18590-601. PubMed ID: 26087180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of adamantane based highly potent HDAC inhibitors.
    Gopalan B; Ponpandian T; Kachhadia V; Bharathimohan K; Vignesh R; Sivasudar V; Narayanan S; Mandar B; Praveen R; Saranya N; Rajagopal S; Rajagopal S
    Bioorg Med Chem Lett; 2013 May; 23(9):2532-7. PubMed ID: 23538115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
    Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
    Xie R; Li Y; Tang P; Yuan Q
    Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
    Liu Y; Salvador LA; Byeon S; Ying Y; Kwan JC; Law BK; Hong J; Luesch H
    J Pharmacol Exp Ther; 2010 Nov; 335(2):351-61. PubMed ID: 20739454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
    Dong G; Chen W; Wang X; Yang X; Xu T; Wang P; Zhang W; Rao Y; Miao C; Sheng C
    J Med Chem; 2017 Oct; 60(19):7965-7983. PubMed ID: 28885834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response.
    Wu WC; Liu YM; Lin MH; Liao YH; Lai MJ; Chuang HY; Hung TY; Chen CH; Liou JP
    Eur J Med Chem; 2020 Apr; 192():112158. PubMed ID: 32171161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.